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Background: The purpose of this study was to evaluate the efficacy and feasibility of carbon ion radiotherapy
(CIRT) for oligo-recurrent lung tumors from colorectal cancer (CRC).
Methods: From May 1997 to October 2012, 34 consecutive patients with oligo-recurrent pulmonary metastases
from CRC were treated with CIRT. The patients were not surgical candidates for medical reasons or patient refusal.
Using a respiratory-gated technique, carbon ion therapy was delivered with curative intent using 4 coplanar beam
angles. A median dose of 60 GyE (range, 44–64.8 GyE) was delivered to the planning target volume (PTV), with a
median daily dose of 15 GyE (range, 3.6–44 GyE). Treatment outcome was analyzed in terms of local control rate
(LCR), survival rate, and treatment-related complications.
Results: In total, 34 patients with 44 oligo-recurrent pulmonary lesions were treated with CIRT. Median follow-up
period was 23.7 months. The 2- and 3-year actuarial LCRs of the treated patients were 85.4% ± 6.2% and 85.4% ± 6.2%,
respectively. Overall survival was 65.1% ± 9.5% at 2 years, and 50.1% ± 10.5% at 3 years. Although survival rates
were relatively worse in the subsets of patients aged < 63 years or with early metastasis (< 36 months after resection
of primary site), these factors were not significantly correlated with overall survival (P = 0.13 and 0.19, respectively). All
treatment-related complications were self-limited, without any grade 3–5 toxicity.
Conclusions: CIRT is one of the most effective nonsurgical treatments for colorectal lung metastases, which are
relatively resistant to stereotactic body radiotherapy. CIRT is considered to be the least invasive approach even in
patients who have undergone repeated prior thoracic metastasectomies.
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Colorectal cancer (CRC) is the third most commonly di-
agnosed cancer in the world [1]. The lung is a frequent
site for metastasis after definitive therapy of CRC, with
pulmonary metastases occurring in approximately 10%
of patients [2,3]. The presence of pulmonary metastases
was previously assumed to represent disseminated incur-
able disease, and palliative chemotherapy was usually* Correspondence: wataru.harry1@gmail.com
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reproduction in any medium, provided the orrecommended. Recent innovations in diagnostic imaging,
such as positron emission tomography/computed tomog-
raphy (PET/CT), allow the detection of small numbers of
metastases, usually confined to one or two locations. Niibe
and Hayakawa proposed the term “oligo-recurrence” to
describe a few metastases with a controlled primary site
and “oligometastases” to describe a similar small number
of metastases with the primary tumor still present. They
stated that, in these cases (particularly in oligo-recurrence),
aggressive local therapy could result in prolonged disease-
free survival with the possibility of cure [4].
For cases with oligo-recurrent pulmonary lesions,
metastasectomy has been considered standard management,ral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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However, a significant proportion of these patients are
not candidates for metastasectomy due to their advanced
age and/or coexistent morbidities such as low pulmonary
function. Similar to strategies in early-stage non-small
cell lung cancer (NSCLC), stereotactic body radiotherapy
(SBRT) and particle radiotherapy, such as carbon ion
radiotherapy (CIRT), have emerged as new treatment
options for metastatic carcinoma [8-15]. Although many
studies have reported favorable outcomes with SBRT for
pulmonary metastases [8-13,15], Takeda et al. reported
that local control after SBRT for lung metastases from
CRC is worse than that from other origins, with a 2-year
LCR of 72% vs 94%, respectively (P < 0.05) [11]. Takahashi
et al. have also demonstrated relatively poor local control
of oligo-recurrent pulmonary lesions in CRC patients
undergoing lung SBRT [13].
In our previous study, we investigated the use of CIRT
as a single modality in oligo-recurrent pulmonary metas-
tases in patients who were not surgical candidates by
evaluating clinical outcomes of CIRT in oligo-recurrent
pulmonary lesions from various primary sites. This is the
only study of CIRT in the management of oligo-recurrent
pulmonary lesions reported to date [14].
Here, we analyze the outcomes in the CRC subpopula-
tion of that study over a longer period of follow-up. To
our knowledge, this study is the first assessment of CIRT
for oligo-recurrent pulmonary metastases from CRC.
Methods
Patient eligibility and pretreatment evaluation
We conducted a retrospective review of 34 consecutive
patients with oligo-recurrent pulmonary metastases from
CRC treated with CIRT at the National Institute of Radio-
logical Sciences (NIRS) from May 1997 to October 2012.
All patients had already undergone radical surgery for
the primary site, which was histologically proven to be
colorectal adenocarcinoma. During follow-up, they de-
veloped oligo-recurrent pulmonary lesions and were not
candidates for surgical resection for medical reasons or
patient refusal. The histology and diagnosis of the meta-
static tumors were determined based on the imaging
findings and clinical course. Pretreatment evaluation
included a complete medical history, physical examin-
ation, chest radiography, computed tomography (CT)
of the chest and abdomen, contrast-enhanced brain
magnetic resonance imaging (MRI), PET/CT scanning,
electrocardiography, pulmonary function tests, and blood
tests. Inclusion criteria for the current study were as
follows: (a) the primary cancer was completely resected,
with no evidence of recurrence; (b) the number of me-
tastases was only one at the time of treatment; (c) no
other distant metastasis in organs other than the lungs;
(d) no systemic therapy such as chemotherapy within1 month of initiation of CIRT; (e) life expectancy of
greater than 6 months, plus adequate pulmonary function.
There were no exclusions regarding tumor size or location
in the lung. Patients developing additional metastases
during follow-up were not excluded. All patients provided
written informed consent before undergoing CIRT. This
study was approved by the institutional review board at
our institution (NIRS-#0504G protocol).
CIRT planning and dose delivery
Details of CIRT planning and delivery at our institution
have been described previously [14,16,17]. Briefly, patients
were immobilized in the supine or prone position with a
custom-made device without an abdominal compressor.
Planning CT images were then acquired with 2.5- or 5.0-
mm-thick slices using a 16-slice CT scanner. These data
were then sent to a three-dimensional radiation treatment
planning system (3D RTPS; HIPLAN, software developed
at NIRS) and respiratory-gated CIRT plans were created
by calculating dose distribution with a parallel broad beam
algorithm. Carbon ion beams of 250 or 290 MeV, depend-
ing on the target size and water equivalent path length
(WEPL) along the beam line, were generated by the Heavy
Ion Medical Accelerator in Chiba (HIMAC) synchrotron.
Gross tumor volume (GTV) was manually delineated in
lung windows in the expiratory phase. Clinical target
volume (CTV) was created by adding over 10 mm margins
to the GTV in all directions. To allow for the intrafrac-
tional motion of the tumor during gated irradiation, a
5-mm internal margin (IM) was added to the CTV in
the craniocaudal direction. Then, the planning target
volume (PTV) was defined as the CTV plus this IM
and a 5-mm safety margin for positioning uncertainty.
In accordance with our routine practice for Stage I
NSCLC, all CIRT plans utilized 4 coplanar and oblique
beam fields at a mutual angle of 40 or 50 degrees. The
total dose was applied to the isocenter, and the PTV
was enclosed conformally at the minimum by the 95%
isodose line with the prescribed dose. CIRT was delivered
at a median total dose of 60 GyE (range, 44–64.8 GyE)
with curative intent. The prescribed dose and fractionation
schedules were determined by reference to the Stage I
NSCLC treatment protocol of the period. A fractionation
regimen of 60.0 GyE in 4 fractions was the schedule most
commonly used for the treatment of 31 of 44 total lesions.
Figure 1 shows an example of contours and isodose curves
for a typical case.
Follow-up, evaluation and statistics
After completion of therapy, clinical follow-up included
clinical examination, chest CT, and laboratory tests every
3 months for the first 2 years and every 6 months there-
after. Additional imaging investigations, such as PET/CT,
were ordered if there was clinical suspicion of recurrence.
Figure 1 Carbon ion radiotherapy and radiographic changes in a typical patient. (A) Pre-treatment CT scan of oligo-recurrence in the lung
from colorectal cancer. (B) Radiotherapy plan for oligo-recurrent pulmonary lesion, which received 60 GyE in four fractions. The yellow line indicates
the clinical target volume that was delineated in the expiratory phase. Dose distribution is shown with isodose lines of different colors (color scale on
left side of image). The clinical target volume is fully encompassed by the 95% isodose line. (C) Chest CT scan 16 months after irradiation, revealing no
evidence of recurrence.
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control rate, survival rate, and treatment-related com-
plications. In this study, local recurrence was defined as
a continuous increase in opacity size on CT imaging,
along with either increased maximum standardized up-
take values (SUVmax) ≥ 5 on PET/CT, or biopsy proof
of disease [18].
Skin and lung toxicities were assessed according to
the National Cancer Institute Common Terminology
Criteria for Adverse Events (NCI CTCAE) version 3.0,
with toxicity occurring within 3 months after the initiation
of CIRT classified as acute toxicity. Late toxicity was
graded using the Radiation Therapy Oncology Group
(RTOG)/European Organisation for Research and Treat-
ment of Cancer (EORTC) criteria.
All data are presented as median values with ranges.
Overall survival (OS) was defined as the elapsed time
from the start of CIRT to death or to the last follow-up
date (the last follow-up date was the last hospital visit,
phone, or mail day). Patients lost to follow-up or alive at
the end of the study were considered censored. LCR was
calculated from the initial CIRT date to the first local
recurrence date or the date of the patient’s last visit. OS
and LCR were analyzed using Kaplan-Meier statistics.
Sex, age (≥ 63 vs. < 63 years), primary tumor site (colon
vs. rectum), history of previous systemic chemotherapy,
past history of pulmonary resection for previous metasta-
ses, disease-free interval (DFI, meaning interval between
the date of initial surgery for primary site and start date ofCIRT; ≥ 36 months vs. < 36 months), pretreatment carci-
noembryonic antigen (CEA) level, and maximum diameter
of lung tumor (≥ 18 mm vs. < 18 mm) were analyzed using
the log-rank test. The thresholds of age, DFI, and diam-
eter, were chosen based on the median of each value over




In our database, we identified 34 patients with 44 oligo-
recurrent pulmonary lesions treated with CIRT. Patient
and tumor characteristics are summarized in Table 1.
There were 20 men (59%) and 14 women (41%), and age
ranged from 34 to 79 years with a median of 63 years
at the time of therapy. Karnofsky performance status
(K-PS) of these patients was relatively robust; 2 were
80% (5.9%), 21 were 90% (61.8%), and 11 were 100%
(32.4%). The primary CRC was located in the colon in
15 patients and in the rectum in 19. Eighteen (53%) pa-
tients had received ≥ 1 chemotherapy regimen before
CIRT, and 10 (29%) had undergone previous pulmonary
metastasectomy for other oligo-recurrent pulmonary
lesions. Median CEA before pulmonary CIRT was 3.5 μg/L
(range, 0.5–650.0 μg/L). The median maximum diameter
of metastatic tumors was 18.0 mm (range, 5.0–60.0 mm),
and CTV ranged from 11.4-165.4 mL with a median of
51.7 mL.



















Disease-free interval until lung metastasis (months)
Median 46.3
Range 10.8-100.9
Carcinoembryonic antigen (CEA) before CIRT
Median 3.5
Range 0.5-650.0












60 GyE/4 fr 31
52.8 GyE/4 fr 6
64.8 GyE/12 fr 2
57.6 GyE/16 fr 1
60 GyE/12 fr 1
60 GyE/8 fr 1
48 GyE/8 fr 1
44 GyE/1 fr 1





Abbreviations: CIRT carbon ion radiotherapy.
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single oligo-recurrent pulmonary lesions occurred were
treated with further CIRT in our institution according
to the abovementioned criteria. In total, 4 lesions were
irradiated in 2 patients, 2 lesions were treated in 4 pa-
tients, and only one lesion was treated in 28 patients.
Local control and survival
Median follow-up duration was 23.7 months (range, 6.1 to
167.0 months) in the entire population and 24.4 months
(range, 6.1 to 167.0 months) for those alive. At the time of
last follow-up, 13 patients had died and 16 patients were
disease-free. The 2- and 3-year LCR of the treated patients
were 85.4% (95% CI, 73.2–97.6%) and 85.4% (95% CI,
73.2%–97.6%), respectively (Figure 2), and median time to
local recurrence was 10.8 months. Except for one patient
who died of bacterial pneumonitis, all deaths were due
to local CRC recurrence or metastases (all extrahepatic).
The overall 2- and 3-year survival rates were 65.1%
(95% CI, 46.5%–83.6%) and 50.1% (95% CI, 29.4%–
70.7%), respectively (Figure 2), with a median survival
time of 36.6 months. Eleven of 34 patients (32.4%)
showed a long-term survival of longer than 3 years.
We also analyzed differences in OS on stratification by
various factors. As shown in Figures 3 and 4, patients
aged younger than 63 and those with early metastasis
(short DFI) had relatively worse prognoses than those
with late recurrence, but these differences were notFigure 2 Overall survival and local control in 34 patients with
oligo-recurrent metastatic disease in the lung.
Figure 3 Kaplan-Meier curves for overall survival in 34 patients
with oligo-recurrent metastatic disease in the lung; younger
age (< 63 years old) and older age (≥ 63 years old) (P = 0.13).
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Other factors, including sex, primary site, a history of
chemotherapy or metastasectomy, CEA level before
CIRT, and tumor size, were not significantly associated
with survival (Table 2).Adverse events
All patients completed their CIRT course without inter-
ruption. The most common acute toxicities included
radiation pneumonitis (RP) and dermatitis. Of the 34
patients, 28 patients (82%) and 5 patients (15%) experi-
enced grade 1 (asymptomatic, radiographic findings only)
and grade 2 (symptomatic, not interfering with activities
of daily living) RP, respectively. Transient mild erythema
(grade 1–2) occurred in most patients. No case of grade
3–5 acute or late toxicity has been recorded up to this
writing.Figure 4 Kaplan-Meier curves for overall survival in 34 patients
with oligo-recurrent metastatic disease in the lung; early
metastases subgroup versus late metastases subgroup (P = 0.19).Discussion
Based on the suggestion that patients with oligo-recurrence
experience better survival, various non-surgical modalities
have been used as local treatment for the management
of inoperable oligo-recurrent pulmonary lesions. Many
series have shown that SBRT provides good local control
in ablating lung metastases [8-13,15]. However, given the
relative radioresistance of CRC metastases, dose escalation
would be needed to achieve the same results. Norihisa
et al. proposed dose escalation in SBRT for oligo-recurrent
pulmonary metastases to achieve better local control [8],
but identification of grade 3–5 toxicity in up to 15% of
patients indicates the limitations of raising the dose [19].
Radiofrequency ablation (RFA) is known to provide effect-
ive local therapy for metastatic lung tumors. Petre and
colleagues recently reported the results of RFA in the
treatment of 69 oligo-recurrent pulmonary lesions in
45 CRC patients. Without any serious adverse events,
2- and 3-year local control rates of 77% were promising
and similar to those with SBRT [20]. Although RFA is
safer than surgical resection and effective for unresectable
oligo-recurrent pulmonary lesions, iatrogenic pneumo-
thorax is estimated to occur in 30% to 40% of patients,
and about 35% of this subgroup require treatment with
chest tube placement [20-22].
We report our experience with a series of 34 patients
treated with CIRT for oligo-recurrent pulmonary metasta-
ses from CRC. With a median follow-up of 23.7 months,
the 2-year actuarial LCR and OS were 85.4% and 65.1%,
respectively. CIRT promises good local control of meta-
static CRC and survival comparable to rates achieved with
surgical resection. Despite the medical comorbidities and
advanced age of most patients, it should be noted that
all the patients were treated safely. All treatment-related
complications were self-limited, without any grade 3–5
toxicity. We consider that CIRT is the least invasive ap-
proach to oligo-recurrent pulmonary metastases, even in
patients who have undergone repeated prior pulmonary
metastasectomies. CIRT has the advantage of delivering
a high linear energy transfer (LET) radiation dose to
the target with sparing of uninvolved lung parenchyma
and surrounding critical organs. These characteristics
of CIRT may improve the LCR while diminishing the
likelihood of adverse events.
Salvage CIRT for the relapsing lesion after SBRT has the
potential benefit of high dose delivery in a short treatment
time with markedly low toxicity. This is important topic,
but is beyond the scope of this study and will be evaluated
in our future study. In fact, some local-relapse cases after
SBRT have already treated using CIRT and achieved local
control in our institution. However, no recurrent patients
underwent SBRT was included in this study.
Our analysis of the OS differences stratified by DFI
(Figure 4) showed a nonsignificant trend of shorter DFI
Table 2 Assessment of prognostic factors for overall survival
Factor Group No. of patients 3-year overall surviaval Log-rank test P value
Sex Male 20 62.9% 0.47
Female 14 36.9%
Age (years) ≥63 21 64.0% 0.13
<63 13 25.0%
Primary cancer Colon 15 53.9% 0.87
Rectum 19 44.6%
Previous systematic chemotherapy Yes 18 39.6% 0.79
No 16 56.8%
Previous pulmonary resection No 10 47.6% 0.60
Yes 24 68.1%
Interval between initial surgery and first CIRT ≥36 month 23 67.6% 0.19
<36 months 11 30.3%
CEA before first CIRT <5 20 42.9% 0.98
≥5 14 68.1%
Maximun diameter of lung tumor ≥18 mm 21 51.8% 0.60
<18 mm 13 50.0%
Abbreviations: CEA carcinoembryonic, CIRT carbon ion radiotherapy.
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resection and nonsurgical treatments such as SBRT,
several investigators reported significantly higher OS for
patients with a DFI of greater than 3 years [3,5,8,21].
Limitations
Our study has several limitations. First, the study was
retrospective in its data collection, with a relatively short
follow-up time. Additional follow-up to assess the long-
term impact of CIRT on clinical outcomes is necessary.
No histology was obtained on the lung lesions, some of
which may have been more radiosensitive NSCLCs,
which would have resulted in the overestimation of
treatment effect. Given that all lesions had the typical
imaging appearance of metastatic lung tumors and grew
rapidly during follow-up after primary resection, how-
ever, we consider that the possibility of misdiagnosis was
low. Another limitation is the various dose treatment
protocols using a wide range of dose prescriptions and
variety of fractionation schemes. Given the very good
clinical outcomes, however, CIRT warrants consideration
as a nonsurgical alternative for the management of oligo-
recurrent pulmonary lesions. We recommend the current
standard CIRT regimen of 60 GyE in 4 fractions, the dose
delivered to the majority of our cohort.
Conclusions
Our results indicate that CIRT is one of the most effective
modalities for treatment of oligo-recurrent pulmonary
metastases from CRC, which are relatively resistant to
SBRT. Similar to its use in early-stage NSCLC, CIRT didnot induce severe complications, even in elderly patients
who were not surgical candidates. We suggest that the
best candidates for CIRT are patients with controlled
primary CRC tumors and a single oligometastatic site
in the lung.
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